Share information
167.70 €
+2.51 %
04/07/2025 16:05
+2.51 %
Open
High
Low
Volume
162.75 €
170.40 €
162.70 €
70,526
Latest News
27-Jun-2025
UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder
20-Jun-2025
UCB to present new data from its neurology portfolio at the 11th European Academy of Neurology (EAN) Congress 2025
16-Jun-2025
Transparency notification FMR LLC
12-Jun-2025
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity